Empirical Asset Management LLC Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Empirical Asset Management LLC bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, Holdings Channel reports. The institutional investor bought 929 shares of the medical research company’s stock, valued at approximately $466,000.

Several other institutional investors have also recently made changes to their positions in the stock. Chancellor Financial Group WB LP bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $392,000. Great Lakes Advisors LLC acquired a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $5,644,000. Compass Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $541,000. Stevens Capital Partners bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth $725,000. Finally, BOK Financial Private Wealth Inc. bought a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $1,689,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TMO. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price target for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Trading Up 4.3%

Shares of Thermo Fisher Scientific stock opened at $614.32 on Thursday. The firm has a market cap of $227.14 billion, a PE ratio of 33.05, a P/E/G ratio of 2.40 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock has a fifty day moving average price of $536.26 and a 200-day moving average price of $508.51.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 52,053 shares of company stock valued at $30,643,589 in the last quarter. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.